Drugs / ABO2109
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07683832 | Jul 2026 → Dec 2028 expected | non-small cell lung carcinoma | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07680582 | Jun 2026 overdue | cancer | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT07583953 | Apr 2026 → Jan 2029 expected | cancer | Suzhou Abogen Biosciences Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABO2109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07680582 ↗ |
| Known as | ABO2109 Injection | “Drug: ABO2109 Injection personalized cancer vaccine” NCT07583953 ↗ |
| Modality | Vaccine | “personalized cancer vaccine” NCT07583953 ↗ |
| Route | Intramuscular | “via an intramuscular (IM) injection” NCT07583953 ↗ |